{
    "root": "2fab399e-2a43-5134-e063-6294a90ae09a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate",
    "value": "20250306",
    "ingredients": [
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "DEXTROAMPHETAMINE SACCHARATE",
            "code": "G83415V073"
        },
        {
            "name": "AMPHETAMINE ASPARTATE MONOHYDRATE",
            "code": "O1ZPV620O4"
        },
        {
            "name": "DEXTROAMPHETAMINE SULFATE",
            "code": "JJ768O327N"
        },
        {
            "name": "AMPHETAMINE SULFATE",
            "code": "6DPV8NK46S"
        }
    ],
    "indications": "dextroamphetamine saccharate , amphetamine aspartate , dextroamphetamine sulfate amphetamine sulfate tablets indicated treatment attention deficit hyperactivity disorder ( adhd ) narcolepsy . attention deficit hyperactivity disorder ( adhd ) diagnosis attention deficit hyperactivity disorder ( adhd ; dsm-iv ® ) implies presence hyperactive-impulsive inattentive symptoms caused impairment present age 7 years . symptoms must cause clinically significant impairment , e.g . , social , academic , occupational functioning , present two settings , e.g . , school ( work ) home . symptoms must better accounted another mental disorder . inattentive type , least six following symptoms must persisted least 6 months : lack attention details/careless mistakes ; lack sustained attention ; poor listener ; failure follow tasks ; poor organization ; avoids tasks requiring sustained mental effort ; loses things ; easily distracted ; forgetful . hyperactive-impulsive type , least six following symptoms must persisted least 6 months : fidgeting/squirming ; leaving seat ; inappropriate running/climbing ; difficulty quiet activities ; “ go ; ” excessive talking ; blurting answers ; ca n't wait turn ; intrusive . combined type requires inattentive hyperactive-impulsive criteria met .",
    "contraindications": "regardless indication , amphetamines administered lowest effective , individually adjusted according therapeutic needs response patient . late evening doses avoided resulting insomnia . attention deficit hyperactivity disorder recommended children 3 years age . children 3 5 years age , start 2.5 mg daily ; daily may raised increments 2.5 mg weekly intervals optimal response obtained . children 6 years age older , start 5 mg twice daily ; daily may raised increments 5 mg weekly intervals optimal response obtained . rare cases necessary exceed total 40 mg per day . give first dose awakening ; additional doses ( 1 2 ) intervals 4 6 hours . prior treating patients dextroamphetamine saccharate , amphetamine aspartate , dextroamphetamine sulfate amphetamine sulfate tablets assess : • presence cardiac disease ( i.e . , perform careful history , family history sudden death ventricular arrhythmia , physical exam ) [ ] . • family history clinically evaluate patients motor verbal tics tourette ’ syndrome initiating dextroamphetamine saccharate , amphetamine aspartate , dextroamphetamine sulfate amphetamine sulfate tablets [ ] . narcolepsy usual dose 5 mg 60 mg per day divided doses , depending individual patient response . narcolepsy seldom occurs children 12 years age ; however , , dextroamphetamine sulfate may used . suggested initial dose patients aged 6 12 5 mg daily ; daily dose may raised increments 5 mg weekly intervals optimal response obtained . patients 12 years age older , start 10 mg daily ; daily may raised increments 10 mg weekly intervals optimal response obtained . bothersome appear ( e.g . , insomnia anorexia ) , reduced . give first dose awakening ; additional doses ( 1 2 ) intervals 4 6 hours .",
    "warningsAndPrecautions": "5 mg : white white , oval shaped , biconvex tablets , double scored one side debossed “ g 5 ” “ 111 ” side . bottles 30 tablets ndc 70010-111-03 bottles 100 tablets ndc 70010-111-01 7.5 mg : white white , round , flat faced , beveled edge tablets , double scored one side debossed “ g 7.5 ” “ 112 ” side . bottles 30 tablets ndc 70010-112-03 bottles 100 tablets ndc 70010-112-01 10 mg : white white , oval shaped , flat faced , beveled edge tablets , double scored one side debossed “ g 10 ” “ 113 ” side . bottles 30 tablets ndc 70010-113-03 bottles 100 tablets ndc 70010-113-01 12.5 mg : white white , oval shaped , biconvex tablets , double scored one side debossed “ g 12.5 ” “ 114 ” side . bottles 30 tablets ndc 70010-114-03 bottles 100 tablets ndc 70010-114-01 15 mg : white white , round , flat faced , beveled edge tablets , double scored one side debossed “ g 15 ” “ 115 ” side . bottles 30 tablets ndc 70010-115-03 bottles 100 tablets ndc 70010-115-01 20 mg : white white , oval shaped , flat faced , beveled edge tablets , double scored one side debossed “ g 20 ” “ 116 ” side . bottles 30 tablets ndc 70010-116-03 bottles 100 tablets ndc 70010-116-01 30 mg white white , oval shaped , biconvex tablets , double scored one side debossed “ g 30 ” “ 117 ” side . bottles 30 tablets ndc 70010-117-03 bottles 100 tablets ndc 70010-117-01 dispense tight , light-resistant container . store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . dispense medication guide available : https : //granulespharma.com/product/mixed-salts-amphetamine-tab/ manufactured : granules pharmaceuticals inc. , chantilly , va 20151 rev . 06/2024",
    "adverseReactions": "patients known hypersensitive amphetamine , components dextroamphetamine saccharate , amphetamine aspartate , dextroamphetamine sulfate amphetamine sulfate tablets . hypersensitivity angioedema anaphylactic reported patients treated amphetamine products [ ] . patients taking monoamine oxidase inhibitors ( maois ) , within 14 days stopping maois ( including maois linezolid intravenous methylene blue ) , increased risk hypertensive crisis [ ] .",
    "indications_original": "Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.\n                  \n                  \n                     Attention Deficit Hyperactivity Disorder (ADHD)\n                  \n                  \n                  A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV\n  ®) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go;” excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.",
    "contraindications_original": "Regardless of indication, amphetamines should be administered at the lowest effective dosage, and dosage should be individually adjusted according to the therapeutic needs and response of the patient. Late evening doses should be avoided because of the resulting insomnia.\n                  \n                  \n                     Attention Deficit Hyperactivity Disorder\n                  \n                  \n                  Not recommended for children under 3 years of age. In children from 3 to 5 years of age, start with 2.5 mg daily; daily dosage may be raised in increments of 2.5 mg at weekly intervals until optimal response is obtained.\n                  \n                  In children 6 years of age and older, start with 5 mg once or twice daily; daily dosage may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. Only in rare cases will it be necessary to exceed a total of 40 mg per day. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.\n                  \n                     \nPrior to treating patients with Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets assess:\n \n                  \n                     \n• for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) [see \n  \n                        WARNINGS\n                     ].\n  \n• the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome before initiating Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets [see \n  \n                        WARNINGS\n                     ].\n \n                  \n                  \n                     Narcolepsy\n                  \n                  \n                  Usual dose 5 mg to 60 mg per day in divided doses, depending on the individual patient response.\n                  \n                  Narcolepsy seldom occurs in children under 12 years of age; however, when it does, dextroamphetamine sulfate may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia), dosage should be reduced. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.",
    "warningsAndPrecautions_original": "5 mg: White to off white, oval shaped, biconvex tablets, double scored on one side and debossed with “G 5” above “111” on other side.\n                  \n                  \n                  Bottles of 30 Tablets NDC 70010-111-03\n                  Bottles of 100 Tablets NDC 70010-111-01\n  \n                     \n7.5 mg: White to off white, round, flat faced, beveled edge tablets, double scored on one side and debossed with “G 7.5” above “112” on other side.\n \n                  \n                  \n                  Bottles of 30 Tablets NDC 70010-112-03\n                  Bottles of 100 Tablets NDC 70010-112-01\n  \n                     \n10 mg: White to off white, oval shaped, flat faced, beveled edge tablets, double scored on one side and debossed with “G 10” above “113” on other side.\n \n                  \n                  \n                  Bottles of 30 Tablets NDC 70010-113-03\n                  Bottles of 100 Tablets NDC 70010-113-01\n  \n                     \n12.5 mg: White to off white, oval shaped, biconvex tablets, double scored on one side and debossed with “G 12.5” above “114” on other side.\n \n                  \n                  \n                  Bottles of 30 Tablets NDC 70010-114-03\n                  Bottles of 100 Tablets NDC 70010-114-01\n  \n                     \n15 mg: White to off white, round, flat faced, beveled edge tablets, double scored on one side and debossed with “G 15” above “115” on other side.\n \n                  \n                  \n                  Bottles of 30 Tablets NDC 70010-115-03\n                  Bottles of 100 Tablets NDC 70010-115-01\n                  \n                     \n20 mg: White to off white, oval shaped, flat faced, beveled edge tablets, double scored on one side and debossed with “G 20” above “116” on other side.\n \n                  \n                  \n                  Bottles of 30 Tablets NDC 70010-116-03\n                  Bottles of 100 Tablets NDC 70010-116-01\n  \n                     \n30 mg White to off white, oval shaped, biconvex tablets, double scored on one side and debossed with “G 30” above “117” on other side.\n \n                  \n                  \n                  Bottles of 30 Tablets NDC 70010-117-03\n  \nBottles of 100 Tablets NDC 70010-117-01\n  \n                     \nDispense in a tight, light-resistant container.\n \n                  \n                  \n                  \n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n                  \n                  \n                  \n                  \n                  \n                  \n                  \n                  \n                  Dispense with Medication Guide available at:\n  \nhttps://granulespharma.com/product/mixed-salts-amphetamine-tab/\n \n                  \n                  \n                  \n                  \n                  \n                  \n                  \n                  \n                  \n                  Manufactured by:\n  \n                     Granules Pharmaceuticals Inc.,\n                     \nChantilly, VA 20151\n  \n                     \nRev. 06/2024",
    "adverseReactions_original": "In patients known to be hypersensitive to amphetamine, or other components of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see \n  \n                        ADVERSE REACTIONS\n                     ].\n \n                  \n                  Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see \n  \n                        WARNINGS\n                      and \n  \n                        DRUG INTERACTIONS\n                     ]."
}